MedTrace Logo

Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis

NCT04027491 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-07-22

No results posted yet for this study

Summary

This study is aimed to test the efficacy and feasibility of an immersive virtual reality (VR) rehabilitation programs to improve upper-limb motor functions in 24 patients with multiple sclerosis (pwMS), characterized by moderate to severe upper-limb motor dysfunctions. In particular, this study will evaluate the efficacy of VR as novel opportunities to increase treatment engagement and rehabilitation effects.

The effectiveness of the rehabilitation program will be assessed using both clinical tests and state-of-the art motion capture system for human movement analysis.

Conditions

Interventions

BEHAVIORAL

Virtual Reality

The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session. The intervention treatment consists of 12 sessions in 4-week period.

Sponsors & Collaborators

  • Italian Multiple Sclerosis Foundation

    collaborator OTHER

  • Fondazione Don Carlo Gnocchi Onlus

    collaborator OTHER

  • Azienda Sanitaria Locale di Cagliari

    collaborator OTHER

  • University of Cagliari

    lead OTHER

Principal Investigators

  • Massimiliano Pau, PhD · University of Cagliari

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2021-06-03
Completion
2022-06-03

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04027491 on ClinicalTrials.gov